Long-term body mass index changes in obese adults and the risk of heart failure, cardiovascular disease and mortality: a longitudinal study of 260,000 adults

Barbara Iyen (barbara.iyen@nottingham.ac.uk)
University of Nottingham School of Medicine
https://orcid.org/0000-0001-9720-1180

Stephen Weng
University of Nottingham School of Medicine

Yana Vinogradova
University of Nottingham School of Medicine

Ralph Akyea
University of Nottingham School of Medicine

Nadeem Qureshi
University of Nottingham School of Medicine

Joe Kai
University of Nottingham School of Medicine

Research article

Keywords: Obesity, overweight, body mass index (BMI), BMI trajectory, cardiovascular disease, heart failure

DOI: https://doi.org/10.21203/rs.3.rs-65564/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Although obesity is a well-recognised risk factor for cardiovascular disease (CVD), the impact of long-term body mass index (BMI) changes in overweight or obese adults, on the risk of heart failure, CVD and mortality has not been quantified.

Methods: This population-based cohort study used routine UK primary care electronic health data linked to secondary care and death-registry records. We identified adults who were overweight or obese, free from CVD and who had repeated BMI measures. Using group-based trajectory modelling, we examined the BMI trajectories of these individuals and then determined incidence rates of CVD, heart failure and mortality associated with the different trajectories. Cox-proportional hazards regression determined hazards ratios for incident outcomes.

Results: 264,230 individuals (mean age 49.5 years (SD 12.7) and mean BMI 33.8kg/m^2 (SD 6.1)) were followed-up for a median duration of 10.9 years. Four BMI trajectories were identified, corresponding at baseline, with World Health Organisation BMI classifications for overweight, class-1, class-2 and class-3 obesity respectively. In all four groups, there was a small, stable upwards trajectory in BMI (mean BMI increase of 1.06kg/m^2 (± 3.8)). Compared with overweight individuals, class-3 obese individuals had a 3.3-fold increased risk of heart failure (HR 3.26 (95% CI 2.98-3.57)), 2.7-fold increased risk of all-cause mortality (HR 2.72 (2.58-2.87)) and 3.3-fold increased risk of CVD-related mortality (HR 3.31 (2.84-3.86)) after adjusting for baseline demographic and cardiovascular risk factors.

Conclusion: The majority of adults who are overweight or obese retain their degree of overweight or obesity over the long term. Individuals with stable severe obesity experience the worst heart failure, CVD and mortality outcomes. These findings highlight the high cardiovascular toll exacted by continuing failure to tackle obesity.

Introduction

Obesity and overweight increase the risk of cardiovascular disease[1] and heart failure[2], and are important causes of morbidity and mortality globally. In 2016, an estimated 1.9 billion adults globally were overweight, of which 650 million were obese [3]. In recent UK estimates from the Health Survey of England [4], 27% of adults were obese, and the proportion of overweight and obese adults increased from 53% in 1993 to 63% in 2017 [4].

A meta-analysis has shown that for every 5-unit increase in BMI, there is a 29% increase in the risk of coronary heart disease (CHD) which drops to 16% after adjustment for blood pressure and cholesterol levels[5]. Long-term weight loss in obese individuals through self-guided efforts or behavioural interventions is not always sustained. Most behavioural interventions in obese individuals achieve only modest weight loss ranging from only -0.3 to -3.1kg at 12 months to -0.3 to +1.3kg weight gain at 24 months[6], and many severely obese individuals remain severely obese for at least 5 years[7]. It is thought that a multi-disciplinary approach and intervention is required to prevent obesity, reduce progression to
more severe forms and lead to substantive and sustainable public health outcomes[8]. While weight loss interventions may improve cardiovascular risk factors[9]metabolic function[10] or, it is unclear what the long term effect of weight changes are on cardiovascular endpoints.

Few studies have explored how BMI in overweight or obese individuals may change over time, and any cardiovascular impact this may have. No existing research on BMI trajectories over time [12-16] has focused entirely on obese and overweight adult populations, so the BMI course of these individuals is unknown. This aim of this study was firstly to examine BMI trajectories in the general population of adults who were overweight or obese adults; and secondly to explore the risk of heart failure, cardiovascular disease (CVD), CVD-related mortality and all-cause mortality, associated with different BMI trajectories.

**Methods**

*Source of Data*

We conducted a cohort study using data from the UK Clinical Practice Research Datalink (CPRD), a nationally representative database of routinely recorded primary care electronic health records [17]. General practice is the first point of contact for non-emergency healthcare in the UK, and over 98% of the UK population are registered with a General Practitioner. The CPRD database contains anonymised longitudinal data entered during routine consultations from general practices who have agreed to provide patient data. The database has a coverage rate of approximately 15% of the UK population and patients are broadly representative of the UK general population in terms of age, sex and ethnicity [17]. Patient records were available from 790 general practices which contributed to the database during the study period from 1999 to 2018. Primary care records from CPRD were linked with secondary care records (Hospital Episode Statistics) and death registration records from the Office of National Statistics (ONS). Data access and ethical approval was granted by the CPRD Independent Scientific Advisory Committee (Protocol number 18_195).

*Study participants and covariates*

We identified individuals aged 18 years or older, with a recorded or computed BMI (weight divided by the square of height) of 25kg/m$^2$ or greater, and subsequent records of BMI during the study period. Each individual could have up to five BMI data points – the first recorded overweight or obese BMI was defined as the baseline BMI, and then subsequent BMI measures at 2 years (±90 days), 5 years (±6 months), 8 years (±6 months) and 10 years (±12 months). To be included in the study, participants had to be registered with the general practice for at least one year before the date of their baseline BMI. Individuals with pre-existing records of CVD (defined as coronary heart disease, peripheral vascular disease, stroke or transient ischaemic attack) or heart failure, were excluded from the study. All participants were followed up until diagnosis of CVD, heart failure, death, transfer out of the practice or last date of data collection, whichever occurred first. To ensure that there were sufficient BMI records for the trajectory analyses, we
included only individuals who had BMI records at baseline and at least one other defined time point, prior to the incidence of CVD, heart failure or death.

In all study participants, we collected data on covariates such as patient demographics (age, sex, ethnicity and socioeconomic status) as well as comorbidities that could alter their risk of developing CVD or heart failure[18]. Our measure of material socioeconomic deprivation was the 2015 English index of multiple deprivation (IMD) in quintiles[19], and this was available for individuals with linked secondary-care records. Records of comorbidities collected at baseline were type-2 diabetes, atrial fibrillation, chronic kidney disease, hypertension, rheumatoid arthritis and other inflammatory diseases. Smoking status and records of alcohol consumption were collected at baseline as well as at the 2-year, 5-year, 8-year and 10-year follow-up time points.

**Outcome ascertainment**

Incident CVD was defined as any new clinical diagnosis of coronary heart disease, stroke, transient ischaemic attack (TIA) or peripheral vascular disease. CVD, heart failure and death records were identified from individuals’ primary care, secondary care and ONS death registry records during the study period. Disease codes used for identification of CVD and heart failure are shown in the supplementary online file.

**Analyses**

Analyses were conducted using Stata SE version 15. Baseline descriptive statistics were presented for the entire study population, including missing data. Although the inclusion criteria ensured that individuals had a minimum of 2 BMI records (BMI at baseline and a minimum of one other BMI record), all values of BMI that were missing at the study set time points and before the incidence of CVD, heart failure or death, were estimated using multiple imputation by chained equations procedure. This approach provides estimates for missing values when data are assumed to be missing at random[20]. It is also the recommended approach for handing missing weight data in epidemiological studies using primary care health records [21], where the practical analytical approach is to include in the imputation model, variables that are predictive of the missing data [22]. Previous research has shown that the use of multiple imputation for missing weight records in primary care databases provided results comparable with population surveys [23]. Baseline BMI, demographic variables such as age and sex, clinical comorbidities (cardiovascular disease, diabetes, hypertension, rheumatoid arthritis and other inflammatory conditions, chronic kidney disease and atrial fibrillation), smoking status and alcohol consumption were included in the imputation models to create 10 imputed datasets. Body mass index measures at baseline, 2 years, 5 years, 8 years and 10 years were used to assign individuals into trajectories of BMI using group based trajectory modelling (GBTM). GBTM provides a statistical method to identify distinctive clusters of individuals who follow a similar developmental trajectory and enables profiling of the characteristics of individuals within the clusters[24]. In the GBTM models, BMI was the dependent variable and time (baseline, 2, 5, 8 and 10 year time-points) was the independent variable. Models took account of the effect of time-varying covariates: age, smoking status and alcohol consumption on individuals’ probability of group membership, and assigned individuals to the group to
which they had the highest probability. The Stata plug-in program (Traj) was used to estimate group-based trajectory models using the maximum likelihood estimation method[25]. Data was modelled using the censored normal distribution and BMI values that were considered clinically implausible (BMI less than 10kg/m$^2$ or greater than 131kg/m$^2$) were excluded from analyses. The Bayesian information criterion (BIC) was used as criterion for selection of the best-fitting trajectory model whereby models with the lower value of BIC was preferred. BIC captures generalised trends over time while also minimising the risk of over-fitting the models. While the Akaike’s information criterion (AIC) and BIC both aim at achieving a compromise between model goodness of fit and model complexity, with maximum likelihood estimates driven to penalise free parameters, BIC are more stringent than AIC [26] and is asymptotically consistent, in that it will select the true model if, among other assumptions, the true model is among the candidate models considered[27]. Similar to GBTM methods employed in a previous study[28], we identified the ideal number of trajectory groups for our study population, by estimating the BIC in 2-group models, 3-group models and 4-group models. This was followed by testing zero-order, linear, quadratic and cubic specifications for the different trajectory shapes until the best fitting shape was derived. In selecting the final model, we ensured each trajectory group had a minimum of 5% of the study population. The 4-group model with four cubic trajectories was selected as the model with the best fit due to the low BIC value as well as having an adequate proportion of the study population per trajectory group (BIC data are shown in supplementary Table 1).

Socio-demographic characteristics, clinical profile, comorbidities as well as CVD, heart failure and mortality outcomes were assessed for individuals in the trajectory groups. Baseline characteristics of individuals between BMI trajectory groups were compared using the ANOVA test for continuous variables or the chi-test for categorical variables. We used survival analyses to estimate the incidence rates of outcomes for individuals in the different trajectory groups. The proportional hazards assumption was checked using statistical tests (Schoenfeld residuals). Multivariate Cox proportional hazards modelling was used to derive hazards ratios for CVD, heart failure and mortality in the groups, adjusting for demographic and clinical covariates that were significantly associated with the exposure and outcome, and using the lowest BMI trajectory group as the reference for comparison. We then estimated the mean change in BMI over the 10 year period, in the subgroup of individuals who had BMI data at 10 years. To assess the validity of our assumption that missing data were missing at random, a sensitivity analyses was done using complete case analyses. Owing to the possibility that not all CVD events are captured are recorded in primary care records, further sensitivity analyses was restricted to only individuals whose primary care records were linked with secondary care (hospital episode statistics) and the ONS (for mortality records).

Results

Study population

A total of 264,230 overweight and obese individuals were included in the study. The flowchart in Figure 1 demonstrates how the study population were derived from the overall CPRD population of obese and
overweight subjects.

Baseline characteristics of the study subjects are shown in Table 1. Females comprised 62% of individuals in the study, the mean age at baseline was 42.5 (SD 12.7) years and the mean BMI was 33.8 (SD 6.1) kg/m$^2$. Linkage with hospital and death registration data was available for 138,755 (52.5%) individuals in CPRD. There were complete BMI records at all 5 set time points for 17.3% of the study population. 20% of subjects had 4 BMI records and 30% had 3 BMI records. Multiple imputation was used to estimate missing BMI values to ensure BMI records were available at all set times prior to the incidence of CVD, heart failure or death. Ethnicity records were available for 69.2% of the study population, with the majority of individuals being white (63.7%). The most prevalent comorbidities at baseline were hypertension (19.9%) and type 2 diabetes (8.6%).

In the study population of 264,230 overweight or obese adults, we identified four distinct BMI trajectories over time, with a statistically significant difference in the BMI at baseline for individuals in the different trajectories (p<0.001). The estimates for posterior probability of group membership are shown in Supplementary table 2. Across the trajectory groups, the average posterior probability was greater than 0.93, which is above the recommended minimum average probability of 0.70, and the odds of correct classification for the BMI GBTM groups were above 30 for all groups, indicating good accuracy of model assignment (Supplementary Table 2).

The mean BMI at baseline, for individuals in trajectory group 1 (n=95,944, 36.3%) was 28.7kg/m$^2$, corresponding to the WHO overweight BMI category. Individuals in trajectory group 2 (n=104,616, 39.6%) had a mean baseline BMI of 33.7kg/m$^2$ corresponding to WHO class 1 obesity category. The mean baseline BMI in trajectory group 3 (n=50,866, 19.3%) was 39.9kg/m$^2$ corresponding to WHO class 2 obesity while those in trajectory group 4 (n=12,804, 4.9%) had a mean baseline BMI of 49.1kg/m$^2$ corresponding to WHO class 3 obesity. Although BMI remained relatively stable across the 4 trajectory groups, individuals had a mean BMI increase of 1.06kg/m$^2$ (± 3.8) over 10 years (Figure 2).

The characteristics of individuals belonging to the different BMI trajectory groups are shown in table 2. Compared to other trajectory groups, the obese class 3-stable trajectory group comprised of the highest proportion of females. There were greater levels of deprivation among particularly the most severely obese trajectory groups. There was also an increasing trend in the prevalence of clinical morbidities such as hypertension, atrial fibrillation, chronic kidney disease and type 2 diabetes, with increasing severity of obesity, such that individuals in the overweight-stable trajectory group had the lowest prevalence whereas those in obese class 3-stable trajectory group had the highest prevalence of comorbidities at baseline.

Cardiovascular disease, heart failure and mortality outcomes

There were a total of 30,400 incident cases of cardiovascular disease over 2,829,075 person-years of follow-up (median follow-up of 10.9 years (IQR 7.0-14.1)). Table 3 shows the overall CVD incidence rates as well as incidence rates of coronary heart disease (CHD), stroke/transient ischemic attack (TIA),
peripheral vascular disease, heart failure, and mortality in the trajectory groups. The incidence rate of CVD in the entire study population (per 1,000 person-years) was 10.75 (95% CI 10.61-10.87). The CVD incidence rate (per 1,000 person-years) among individuals in the overweight-stable trajectory group was 9.30 (9.12-9.49). Higher incidence rates of overall CVD and CVD subtypes were observed in obese class 1-stable trajectory group compared to overweight-stable individuals but no further increase in incidence rates of CHD, stroke/TIA or peripheral vascular disease, with more severe categories of obesity from obese class 1-stable to obese class 3-stable groups. There was however a substantial and significant gradient in heart failure incidence with increasing severity of obesity from overweight-stable to obese class 3-stable trajectory groups, such that heart failure incidence rate (per 1,000 person years) in overweight-stable trajectory individuals was 1.70 (1.6-1.8), and 5.70 (5.3-6.1) in obese class 3-stable trajectory individuals (score test for trend across BMI groups p<0.0001).

A total of 24,022 deaths occurred during the period of follow-up, of which 2,827 (11.8%) were cardiovascular deaths. The overall mortality rate in the study population (per 1,000 person-years) was 8.5 (8.4-8.6). All-cause mortality and CVD-related mortality rates increased with more severe categories of obesity (shown in table 3). As well as having the earliest onset of incident CVD, obese class 3-stable trajectory individuals had the highest all-cause mortality rate, CVD-related mortality rate and the youngest age at death.

Table 4 shows the hazards ratios for CVD, heart failure and mortality outcomes for individuals in obese 1-stable, obese 2-stable and obese 3-stable trajectory groups, compared to individuals in the overweight-stable trajectory group. Statistical tests of Cox proportional hazards assumption found Cox proportional analyses suitable for hazards ratio analyses (Schoenfeld test in stata; p=0.105). After adjusting for age, sex and comorbidities, individuals in obese class 1, 2 and 3 trajectory groups had higher risks of all CVD, heart failure and mortality outcomes, compared to individuals in the overweight-stable trajectory group. An increase in coronary heart disease and stroke/TIA risk was observed in obese class 1-stable compared to overweight individuals but no further increase in risk of these conditions were found with more severe categories of obesity. There was no increase in the risk of peripheral vascular disease in adults who were obese compared to those who were in the overweight group. The risk of heart failure, all-cause mortality and CVD-related mortality increased considerably with increasing severity of obesity such that after adjusting for age, sex and comorbidities, individuals in obese class 3-stable trajectory group had a 3.3-fold increased risk of heart failure, 3.3-fold increased risk of CVD-related deaths and a 2.7-fold increased risk of all-cause mortality, compared to individuals in the overweight-stable trajectory group.

Figure 3 illustrates the cumulative outcome-free survival of individuals in the trajectory groups.

In sensitivity analyses done using only the BMI records available in patients’ electronic health records (without multiple imputation of missing BMI records), four BMI trajectory groups were identified and the BMI measures across the BMI trajectories were similar to measures in the main study which used multiple imputation to estimate missing BMI records. Also, similar to findings in the main study, there was
a small stable upwards trajectory across all 4 groups, with an overall mean BMI increase of 1.26kg/m² (SD 4.47) over 10 years (supplementary Table 3)

In further sensitivity analyses restricted to 138,755 individuals whose primary care records were linked with secondary care and ONS death registration records, the hazards ratios for overall CVD, coronary heart disease, stroke/TIA, heart failure, all-cause mortality and CVD-related death remained significantly higher in obese class 1-stable, class 2-stable and class 3-stable individuals, compared with the overweight-stable trajectory group of individuals. As in the main analyses, there was no observed increase in the risk of peripheral vascular disease in adults who were obese compared to overweight adults (supplementary Table 4).

Discussion

Main findings of paper

In this large general population cohort study of adults who were overweight or obese, we observed a stable upwards BMI trajectory over time whereby most subjects retained their degree of obesity over the long term. The risk of CVD, heart failure and mortality increased with increasing severity of obesity. The increase in risk was however most marked for heart failure and mortality. After adjusting for the effect of age, sex and comorbidities, individuals in the most severely obese group had a 3.3-fold higher risk of heart failure, 3.3 fold higher risk of CVD-related mortality and 2.7-fold higher risk of all-cause mortality compared with overweight individuals. There were greater levels of socioeconomic deprivation with increasing severity of obesity, confirming that this is disproportionately an issue in the materially deprived.

Strengths and limitations

To our knowledge, this is the first and largest study to analyse overweight and obese adults’ BMI trajectories and their impact on CVD endpoints, heart failure, and mortality. We had a large sample size of obese and overweight individuals who were studied prospectively with multiple BMI measures per individual over an extensive follow-up period. Linkage of individuals’ routine electronic primary care records to their secondary care and death registration records, enabled more robust extrapolation of CVD diagnosis and mortality data. The use of health professional-recorded rather than self-reported BMI measures minimised the risk of inaccuracies in the study. By using data from a large nationally representative database of UK electronic health records, the study findings can be generalised to the general population of overweight and obese adults.

Some limitations of this study are recognised. Body mass index is a surrogate measure of adiposity. Body composition of fat and skeletal muscle mass changes with age [29] and differs between sexes and ethnic groups [30]. While other indices such as waist-hip ratio and waist circumference are more suitable and accurate measures of adiposity than BMI, these are not used routinely in clinical practice and are not routinely available in electronic heath records. Over 60% of our study population were White, and so the
CVD risk profile and CVD-related outcomes in the study population may not be directly generalizable to, or may underestimate obesity-related heart failure, CVD and mortality risk in other ethnic populations. There was no information on physical activity level or dietary intake so it remains unclear whether weight change observed in individuals’ was intentional or non-intentional and due to presence of disease. Lastly, a study inclusion criterion was a minimum of 2 BMI entries in subjects’ primary care records so there is a small risk of selection bias in the population studied.

Comparison with existing literature

This is the first study to evaluate the long-term impact of overweight and obese individuals’ BMI trajectory on cardiovascular endpoints, heart failure and mortality outcomes. While the association between obesity and cardiovascular disease is established [1, 2], our study sought to assess the effect of long-term BMI changes, rather than single BMI measures, on the risk of CVD and related outcomes. We particularly observed a strong significant gradient in heart failure risk which increased with more severe forms of obesity. This provides confirmatory evidence of the graded increase in heart failure risk with increasing obesity. The lack of a relationship between degree of obesity and the risk of peripheral vascular disease is similar to findings in the Framingham heart study, and as was previously suggested[31], may be either due to under-diagnosis of peripheral vascular disease, or a difference in the underlying disease mechanism compared to other types of CVD.

In relation solely to obesity, our findings in a large general adult population expand on those of a smaller study of 3,070 Canadian adults which similarly found no significant change in individuals’ BMI over time [32]. Similarly, a retrospective cohort study of 11,735 adults with severe obesity (BMI 35kg/m$^2$ or greater) in the US, found that severely obese individuals remained in that BMI category over at least 5 years [7]. The current study is the largest prospective investigation to assess long term changes in BMI over time. Our finding that the general population of adults who were overweight or obese followed one of four stable upwards BMI trajectories over a decade, elaborates on previous research.

Previous studies of the association between obesity and mortality have produced conflicting results. In the original Framingham heart study and the Framingham offspring study, maximum BMI over a 24 year period was strongly associated with subsequent all-cause mortality [33]. However a systematic review of the risk of all-cause mortality in overweight and obese relative to normal weight individuals in the general population, found lower risk of mortality in overweight compared to normal weight subjects, but the highest mortality risk in more severely obese subjects with class 2 and 3 obesity [34]. More recently, a population-based cohort study found a J-shaped association between BMI and overall mortality such that lower BMI was associated with increased mortality risk, but the absolute mortality burden was predominantly driven by obesity [35]. In the current study, we observed a stepwise increase in the risk of all-cause and CVD-related mortality with increasing severity of obesity. This persisted after adjusting for the effect of age, sex, hypertension, type 2 diabetes, atrial fibrillation and chronic kidney disease. This observed association may be due to several plausible mechanisms. Severe obesity is a risk factor for dyslipidaemia and is associated with devastating health consequences such as obesity hypoventilation
syndrome, obstructive sleep apnoea, liver disease and certain types of cancers [36], which could independently or synergistically increase the risk of mortality.

Some studies have reported an ‘Obesity paradox’ with clinically better outcomes in overweight and obese patients compared to normal weight patients in the context of prevalent cardiovascular disease such as heart failure [37] or following an acute coronary event [38]. In contrast, in the current study population, free from CVD at the start of follow-up, individuals with more severe obesity had earlier onset of incident CVD and earlier age at death, than overweight individuals. Our study provides compelling evidence of poor health outcomes associated with obesity.

Conclusions

Despite widespread efforts to prevent and manage obesity, the majority of adults who are overweight or obese in the general population continue to remain so in the long term. This is associated with a three-fold increase in heart failure, cardiovascular disease and mortality risk in the stably severe obese population. This research highlights the high cardiovascular toll exacted by continuing failure to tackle obesity, particularly among more socio-economically deprived populations. More effective policies and weight-management interventions at societal, cultural and health service levels are needed to address this increasing burden. Further research is also needed to explore whether interventions to change BMI trajectories would have an impact on future CVD outcomes.

Abbreviations

BMI – body mass index
CHD – coronary heart disease
CPRD – Clinical Practice Research datalink
CVD – cardiovascular disease
GBTM – group based trajectory modelling
HES – Hospital Episode Statistics
IMD – Index of Multiple Deprivation
ONS – Office for National Statistics
TIA – Transient ischaemic attack

Declarations
Ethics approval: Data access and ethical approval was granted by the CPRD Independent Scientific Advisory Committee (Protocol number 18_195).

Consent for publication: Not applicable

Availability of data: The CPRD and linked Hospital Episode Statistics datasets analysed during the current study are not publicly available, and can only be accessed following approval by the CPRD Independent Scientific Advisory Committee (ISAC).

Competing interests: The authors have no relevant financial or non-financial interests to disclose.

Funding: BI's clinical academic lectureship is fully funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health & Social Care.

Author contributions: BI conceptualised the study idea, developed the study design, obtained ethical approvals to access data, analysed the data, and wrote the initial manuscript draft and subsequent revisions. SW contributed to conceptualising the study design and methods, interpreted and reviewed study findings and critically reviewed the manuscript. YV was responsible for data extraction and contributed to study design methodology. RA contributed to study design methodology and data management. NQ contributed to conceptualising the study design and interpretation of study findings. JK contributed to conceptualising the study design and methods, overall supervision of the research study, review and interpretation of study findings and critical revision of manuscript. All study authors have contributed to revising, writing and finalising the final draft of the manuscript prior to submission.

Acknowledgements: Not applicable

References

[1] S. S. Khan, H. Ning, J. T. Wilkins, N. Allen, M. Carnethon, J. D. Berry, et al., "Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity," JAMA cardiology, vol. 3, pp. 280-287, 2018.

[2] S. Kenchaiah, J. C. Evans, D. Levy, P. W. F. Wilson, E. J. Benjamin, M. G. Larson, et al., "Obesity and the Risk of Heart Failure," New England Journal of Medicine, vol. 347, pp. 305-313, 2002/08/01 2002.

[3] World Health Organization, "Obesity and overweight," 2018.

[4] E. Fuller, J. Mindell, and G. Prior. Health Survery for England 2015: Adult overweight and obesity [Online]. Available: http://www.content.digital.nhs.uk/catalogue/PUB22610

[5] R. P. Bogers, W. J. E. Bemelmans, R. T. Hoogenveen, H. C. Boshuizen, M. Woodward, P. Knekt, et al., "Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels: A Meta-analysis of 21 Cohort Studies Including More Than 300 000 Persons," JAMA Internal Medicine, vol. 167, pp. 1720-1728, 2007.
[6] S. U. Dombrowski, A. Avenell, and F. F. Sniehott, "Behavioural Interventions for Obese Adults with Additional Risk Factors for Morbidity: Systematic Review of Effects on Behaviour, Weight and Disease Risk Factors," *Obesity Facts*, vol. 3, pp. 377-396, 2010.

[7] E. S. Wong, B. C. Wang, R. Alfonso-Cristancho, D. R. Flum, S. D. Sullivan, L. P. Garrison, *et al.*, "BMI trajectories among the severely obese: results from an electronic medical record population," *Obesity*, vol. 20, pp. 2107-12, Oct 2012.

[8] C. J. Lavie, D. Laddu, R. Arena, F. B. Ortega, M. A. Alpert, and R. F. Kushner, "Healthy Weight and Obesity Prevention: JACC Health Promotion Series," *Journal of the American College of Cardiology*, vol. 72, pp. 1506-1531, 2018/09/25/ 2018.

[9] E. Zomer, K. Gurusamy, R. Leach, C. Trimmer, T. Lobstein, S. Morris, *et al.*, "Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis," *Obesity Reviews*, vol. 17, pp. 1001-1011, Oct 2016.

[10] F. Magkos, G. Fraterrigo, J. Yoshino, C. Luecking, K. Kirbach, S. C. Kelly, *et al.*, "Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity," *Cell metabolism*, vol. 23, pp. 591-601, 02/22 2016.

[11] S. Steven, K. G. Hollingsworth, A. Al-Mrabe, L. Avery, B. Aribisala, M. Caslake, *et al.*, "Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiologival Changes in Responders and Nonresponders," *Diabetes Care*, vol. 39, p. 808, 2016.

[12] K. Dhana, J. van Rosmalen, D. Vistisen, M. A. Ikram, A. Hofman, O. H. Franco, *et al.*, "Trajectories of body mass index before the diagnosis of cardiovascular disease: a latent class trajectory analysis," *European Journal of Epidemiology*, vol. 31, pp. 583-592, 03/08, 11/05/received, 02/22/accepted 2016.

[13] A. Tirosh, I. Shai, A. Afek, G. Dubnov-Raz, N. Ayalon, B. Gordon, *et al.*, "Adolescent BMI trajectory and risk of diabetes versus coronary disease," *New England Journal of Medicine*, vol. 364, pp. 1315-25, Apr 07 2011.

[14] V. V. Kapetanakis, A. R. Rudnicka, A. K. Wathern, L. Lennon, O. Papacosta, D. G. Cook, *et al.*, "Adiposity in early, middle and later adult life and cardiometabolic risk markers in later life; findings from the British regional heart study," *PLoS ONE [Electronic Resource]*, vol. 9, p. e114289, 2014.

[15] H. Xian, T. Vasilopoulos, W. Liu, R. L. Hauger, K. C. Jacobson, M. J. Lyons, *et al.*, "Steeper change in body mass across four decades predicts poorer cardiometabolic outcomes at midlife," *Obesity*, vol. 25, pp. 773-780, Apr 2017.

[16] T. S. Bowman, T. Kurth, H. D. Sesso, J. E. Manson, and J. M. Gaziano, "Eight-year change in body mass index and subsequent risk of cardiovascular disease among healthy non-smoking men," *Preventive medicine*, vol. 45, pp. 436-441, 07/26 2007.
[17] E. Herrett, A. M. Gallagher, K. Bhaskaran, H. Forbes, R. Mathur, T. van Staa, et al., "Data Resource Profile: Clinical Practice Research Datalink (CPRD)," *Int J Epidemiol*, vol. 44, pp. 827-36, Jun 2015.

[18] J. Hippisley-Cox, C. Coupland, and P. Brindle, "Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study," *BMJ*, vol. 357, 2017.

[19] "The English Index of Multiple Deprivation (IMD) 2015 – Guidance," ed, 2015.

[20] A. B. Pedersen, E. M. Mikkelsen, D. Cronin-Fenton, N. R. Kristensen, T. M. Pham, L. Pedersen, et al., "Missing data and multiple imputation in clinical epidemiological research," *Clinical epidemiology*, vol. 9, pp. 157-166, 2017.

[21] I. Petersen, C. A. Welch, I. Nazareth, K. Walters, L. Marston, R. W. Morris, et al., "Health indicator recording in UK primary care electronic health records: key implications for handling missing data," *Clin Epidemiol*, vol. 11, pp. 157-167, 2019.

[22] J. A. C. Sterne, I. R. White, J. B. Carlin, M. Spratt, P. Royston, M. G. Kenward, et al., "Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls," *BMJ*, vol. 338, 2009.

[23] L. Marston, J. R. Carpenter, K. R. Walters, R. W. Morris, I. Nazareth, and I. Petersen, "Issues in multiple imputation of missing data for large general practice clinical databases," *Pharmacoepidemiol Drug Saf*, vol. 19, pp. 618-26, Jun 2010.

[24] D. S. Nagin and C. L. Odgers, "Group-Based Trajectory Modeling in Clinical Research," *Annual Review of Clinical Psychology*, vol. 6, pp. 109-138, 2010/03/01 2010.

[25] B. L. Jones and D. S. Nagin, "A Note on a Stata Plugin for Estimating Group-based Trajectory Models," *Sociological Methods & Research*, vol. 42, pp. 608-613, 2013.

[26] S. Yang and G. Berdine, "Model selection and model over-fitting," *The Southwest Respiratory and Critical Care Chronicles* vol. 3, 2015.

[27] S. I. Vrieze, "Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC)," *Psychological methods*, vol. 17, pp. 228-243, 2012.

[28] D. M. Shearer, W. M. Thomson, J. M. Broadbent, R. McLean, R. Poulton, and J. Mann, "High-risk glycated hemoglobin trajectories established by mid-20s: findings from a birth cohort study," *BMJ Open Diabetes Research &amp; Care*, vol. 4, p. e000243, 2016.

[29] K. J. Rothman, "BMI-related errors in the measurement of obesity," *Int J Obes (Lond)*, vol. 32 Suppl 3, pp. S56-9, Aug 2008.
Table 1. Baseline characteristics of the study population
| Measure                          | Total n (%) | Male n (%) | Female n (%) |
|---------------------------------|-------------|------------|--------------|
| | N=264,230 | N=99,590 | N=164,640 |
| **Years (mean(SD))**            | 49.5 (12.7) | 51.2 (11.7) | 48.5 (13.2) |
| **ss index (kg/m²)**            | 33.8 (6.1)  | 33.2 (5.4)  | 34.2 (6.4)  |
| **Total n (%)**                 | 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **Hispanic**                    | 2,154 (0.8)  | 548 (0.6)   | 1,606 (1.0) |
| **Hispanicibbean**              | 2,059 (0.8)  | 495 (0.5)   | 1,564 (1.0) |
| **Other**                       | 595 (0.2)    | 146 (0.2)   | 449 (0.3)   |
| **Asian**                       | 334 (0.1)    | 98 (0.1)    | 236 (0.1)   |
| **Native American**             | 158 (0.1)    | 56 (0.1)    | 102 (0.1)   |
| **Other races**                 | 2,908 (1.1)  | 1,032 (1.0) | 1,876 (1.1) |
| 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **African American**            | 1,852 (0.7)  | 603 (0.6)   | 1,249 (0.8) |
| **Other races**                 | 595 (0.2)    | 170 (0.2)   | 425 (0.3)   |
| **Native American**             | 1,306 (0.5)  | 518 (0.5)   | 788 (0.5)   |
| **Other races**                 | 2,498 (1.0)  | 920 (0.9)   | 1,578 (1.0) |
| 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **Participants with ethnicity records** | 81,441 (30.8) | 32,131 (32.3) | 49,310 (30.0) |
| **Status**                      |             |            |              |
| **White**                       | 78,539 (29.7) | 37,187 (37.3) | 41,352 (25.1) |
| **Smoker (1-9 cigs/day)**       | 18,053 (6.8) | 7,209 (7.2) | 10,844 (6.6) |
| **Smoker (10-19/day)**          | 13,182 (5.0) | 4,173 (4.2) | 9,009 (5.5) |
| **Smoker (20-39/day)**          | 11,213 (4.2) | 4,622 (4.6) | 6,591 (4.0) |
| **Smoker (40+/day)**            | 142,969 (54.1) | 46,289 (46.5) | 96,680 (58.7) |
| 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **Smoker (40+/day)**            | 274 (0.1)    | 110 (0.1)   | 164 (0.1)   |
| **Consumption**                 |             |            |              |
| **1 unit/day)**                 | 88,408 (33.5) | 28,902 (29.0) | 59,506 (36.1) |
| **2 units/day**                 | 39,423 (14.9) | 19,986 (20.1) | 19,437 (11.8) |
| **3-6 units/day**               | 22,394 (8.5) | 13,231 (13.3) | 9,163 (5.6) |
| **7 units/day**                 | 7,090 (2.7)  | 5,271 (5.3)  | 1,819 (1.1)  |
| **8+ units/day**                | 4,377 (1.7)  | 3,621 (3.6)  | 756 (0.5)    |
| **Alcohol Consumption**         | 9,660 (3.7)  | 4,477 (4.5)  | 5,183 (3.2)  |
| 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
| **Alcohol Consumption**         | 84,698 (32.1) | 21,433 (21.5) | 63,265 (38.4) |
| **Diabetes**                    | 8,180 (3.1)  | 2,669 (2.7)  | 5,511 (3.4)  |
| **Diabetes**                    |             |            |              |
| **Arthritis /inflammatory diseases** | 4,857 (1.8)  | 1,078 (1.1)  | 3,779 (2.3)  |
| 168,330 (63.7) | 62,873 (63.1) | 105,457 (64.1) |
Table 2. Sociodemographic and clinical characteristics by BMI trajectory groups (N=264,230)
| Patient characteristics (Sociodemographic characteristics) | Trajectory 1 (overweight-S) (n=95,944) | Trajectory 2 (Obese 1-S) (n=104,616) | Trajectory 3 (obese 2-S) (n=50,866) | Trajectory 4 (obese 3-S) (n=12,804) |
|---|---|---|---|---|
| Age at start of study (mean(SD)) | 49.5 (13.2) | 49.9 (12.7) | 49.1 (12.2) | 48.8 (11.2) |
| Male gender n (%) | 37,882 (39.5) | 41,685 (39.9) | 16,652 (32.7) | 3,371 (26.3) |
| Smoking | | | | |
| Ex-smoker | 27,950 (29.1) | 31,763 (30.4) | 15,123 (29.7) | 3,703 (28.9) |
| Light smoker (1-9 cigs/day) | 6,918 (7.2) | 7,071 (6.8) | 3,270 (6.4) | 794 (6.2) |
| Moderate smoker (10-19 cigs/day) | 5,118 (5.3) | 5,214 (5.0) | 2,347 (4.6) | 503 (3.9) |
| Heavy smoker (20-39 cigs/day) | 3,827 (4.0) | 4,470 (4.3) | 2,297 (4.5) | 619 (4.8) |
| Non-smoker | 52,070 (54.3) | 55,989 (53.5) | 27,757 (54.6) | 7,153 (55.9) |
| Missing | 61 (0.1) | 109 (0.1) | 72 (0.1) | 32 (0.3) |
| Alcohol consumption | | | | |
| Trivial (< 1 unit/day) | 31,978 (33.3) | 35,035 (33.5) | 17,192 (33.8) | 4,203 (32.8) |
| Light (1-2 units/day) | 16,405 (17.1) | 15,773 (15.1) | 6,133 (12.1) | 1,112 (8.7) |
| Moderate (3-6 units/day) | 9,746 (10.2) | 8,748 (8.4) | 3,314 (6.5) | 586 (4.6) |
| Heavy (7-9 units/day) | 2,883 (3.0) | 2,961 (2.8) | 1,076 (2.1) | 170 (1.3) |
| Very heavy (>9 units/day) | 1,621 (1.7) | 1,905 (1.8) | 722 (1.4) | 129 (1.0) |
| Ex-alcohol consumption | 3,086 (3.2) | 3,759 (3.6) | 2,174 (4.3) | 641 (5.0) |
| No alcohol consumption | 28,076 (29.3) | 33,168 (31.7) | 18,113 (35.6) | 5,341 (41.7) |
| Missing | 2,149 (2.2) | 3,267 (3.1) | 2,142 (4.2) | 622 (4.9) |
| Deprivation (IMD quintile) | | | | |
| 1 (least deprived) | 10,122 (10.6) | 10,251 (9.8) | 4,334 (8.5) | 827 (6.5) |
| 2 | 11,043 (11.5) | 12,124 (11.6) | 5,549 (10.9) | 1,242 (9.7) |
| 3 | 9,644 (10.1) | 11,386 (10.9) | 5,654 (11.1) | 1,386 (10.8) |
| 4 | 9,889 (10.3) | 12,173 (11.6) | 6,412 (12.6) | 1,693 (13.2) |
| 5 (most deprived) | 7,528 (7.9) | 9,818 (9.4) | 5,799 (11.4) | 1,766 (13.8) |
| Missing records | 47,718 (49.7) | 48,864 (46.7) | 23,118 (45.5) | 5,890 (46.0) |
| Weight profile and clinical characteristics | | | | |
| Body mass index in kg/m² (mean(SD)) | | | | |
| Baseline BMI | 28.7 (2.2) | 33.7 (2.7) | 39.9 (3.5) | 49.1 (5.7) |
| BMI at 2 years | 28.6 (2.2) | 33.7 (2.4) | 39.9 (3.2) | 49.1 (5.4) |
| BMI at 5 years | 29.2 (2.3) | 34.5 (2.4) | 40.8 (3.1) | 50.0 (5.3) |
| BMI at 8 years | 29.5 (2.5) | 34.8 (2.6) | 41.1 (3.3) | 50.1 (5.4) |
| BMI at 10 years | 29.7 (2.8) | 34.9 (3.0) | 41.1 (3.7) | 49.8 (5.7) |
Mean BMI change over 10 years | 1.0 (3.1) | 1.2 (3.7) | 1.0 (4.6) | 0.6 (6.3) |
---|---|---|---|---|
Prevalence of comorbidities at baseline
Atrial fibrillation | 671 (0.7) | 865 (0.8) | 452 (0.9) | 156 (1.2) |
Chronic kidney disease | 771 (0.8) | 998 (1.0) | 532 (1.0) | 159 (1.2) |
Hypertension | 15,708 (16.4) | 21,438 (20.5) | 12,009 (23.6) | 3,419 (26.7) |
Type-2 diabetes | 6,384 (6.7) | 8,930 (8.5) | 5,609 (11.0) | 1,921 (15.0) |
Rheum arthritis/inflammatory diseases | 1,674 (1.7) | 1,970 (1.9) | 952 (1.9) | 261 (2.0) |

Table 3. Cardiovascular disease, heart failure and death in the BMI trajectory groups
| Trajectory 1 (overweight-S) (n=95,944) | Trajectory 2 (obese class 1-S) (n=104,616) | Trajectory 3 (obese class 2-S) (n=50,866) | Trajectory 4 (obese class 3-S) (n=12,804) |
|--------------------------------------|------------------------------------------|-------------------------------------|--------------------------------------|
| **vascular disease and heart failure outcomes** | | | |
| mean (SD)) at first CVD diagnosis | 65.9 (12.0) | 66.2 (11.8) | 65.2 (11.8) | 64.1 (10.9) |
| (up (1000 person years) | 1,100 | 1,100 | 517.7 | 123.1 |
| relative risk of events (%) | 10,054 (10.5) | 12,666 (12.1) | 6,137 (12.1) | 1,543 (12.1) |
| (D) | 6,074 (6.3) | 7,569 (7.2) | 3,329 (6.5) | 714 (5.6) |
| TIA | 2,675 (2.8) | 3,152 (3.0) | 1,436 (2.8) | 300 (2.3) |
| Failure | 1,246 (1.3) | 1,425 (1.4) | 595 (1.2) | 108 (0.8) |
| relative rate (95% CI) of CVD and heart failure, per (1,000 person-years) | | | | |
| D | 9.30 (9.1-9.5) | 11.44 (11.2-11.6) | 11.86 (11.6-12.2) | 12.54 (11.9-13.2) |
| my heart disease | 5.62 (5.5-5.8) | 6.83 (6.7-7.0) | 6.43 (6.2-6.7) | 5.80 (5.4-6.2) |
| TIA | 2.48 (2.4-2.6) | 2.85 (2.7-2.9) | 2.77 (2.6-2.9) | 2.44 (2.2-2.7) |
| ral vascular disease | 1.15 (1.1-1.2) | 1.29 (1.2-1.4) | 1.15 (1.1-1.2) | 0.88 (0.7-1.1) |
| Failure | 1.70 (1.6-1.8) | 2.87 (2.8-3.0) | 3.76 (3.6-3.9) | 5.70 (5.3-6.1) |
| ty outcomes | | | | |
| during follow-up (total n=24,022) | 7,938 (8.3) | 9,175 (8.8) | 5,092 (10.0) | 1,817 (14.2) |
| ears) at death (mean(SD)) | 74.5 (12.1) | 73.6 (12.0) | 70.9 (12.3) | 67.3 (11.8) |
| related death n(%) =2,827 | 761 (0.8) | 1,165 (1.1) | 679 (1.3) | 222 (1.7) |
| ty rate (95% CI), per 1,000 person-years | | | | |
| e mortality rate | 7.35 (7.2-7.5) | 8.28 (8.1-8.5) | 9.84 (9.6-10.1) | 14.76 (14.1-15.5) |
| related mortality rate | 0.70 (0.7-0.8) | 1.05 (1.0-1.1) | 1.31 (1.2-1.4) | 1.80 (1.6-2.1) |

Table 4. Risk of CVD outcomes and mortality associated with BMI trajectory groups
| outcome                | Trajectory group | Unadjusted Hazards ratio (95% CI) | Adjusted hazards ratio (95% CI) | Model adjusted for age and sex | Model adjusted for age, sex and comorbidities\(^a\) |
|------------------------|------------------|-----------------------------------|---------------------------------|--------------------------------|-----------------------------------------------|
| all CVD                | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.25 (1.22-1.28)                  | 1.24 (1.21-1.28)                | 1.15 (1.12-1.19)               |                                               |
|                        | obese 2-S        | 1.32 (1.28-1.36)                  | 1.46 (1.41-1.51)                | 1.27 (1.23-1.31)               |                                               |
|                        | obese 3-S        | 1.42 (1.35-1.50)                  | 1.75 (1.66-1.85)                | 1.40 (1.33-1.48)               |                                               |
| coronary heart attack  | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.23 (1.19-1.28)                  | 1.23 (1.18-1.27)                | 1.14 (1.10-1.18)               |                                               |
|                        | obese 2-S        | 1.17 (1.12-1.22)                  | 1.30 (1.24-1.35)                | 1.13 (1.09-1.18)               |                                               |
|                        | obese 3-S        | 1.07 (0.99-1.16)                  | 1.31 (1.22-1.42)                | 1.06 (0.99-1.16)               |                                               |
| ke/ TIA                | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.18 (1.12-1.24)                  | 1.16 (1.10-1.22)                | 1.09 (1.03-1.15)               |                                               |
|                        | obese 2-S        | 1.16 (1.09-1.24)                  | 1.27 (1.19-1.36)                | 1.13 (1.06-1.20)               |                                               |
|                        | obese 3-S        | 1.04 (0.93-1.18)                  | 1.26 (1.12-1.42)                | 1.04 (0.92-1.18)               |                                               |
| peripheral arterial disease | overweight-S | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.13 (1.05-1.22)                  | 1.13 (1.04-1.22)                | 0.99 (0.92-1.07)               |                                               |
|                        | obese 2-S        | 1.02 (0.92-1.12)                  | 1.16 (1.06-1.29)                | 0.92 (0.83-1.01)               |                                               |
|                        | obese 3-S        | 0.79 (0.65-0.96)                  | 1.03 (0.85-1.25)                | 0.73 (0.60-0.89)               |                                               |
| rt failure             | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.73 (1.63-1.83)                  | 1.73 (1.63-1.83)                | 1.51 (1.42-1.60)               |                                               |
|                        | obese 2-S        | 2.31 (2.16-2.46)                  | 2.70 (2.53-2.88)                | 2.09 (1.96-2.23)               |                                               |
|                        | obese 3-S        | 3.58 (3.28-3.91)                  | 4.94 (4.53-5.40)                | 3.26 (2.98-3.57)               |                                               |
| cause mortality        | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.16 (1.13-1.20)                  | 1.16 (1.12-1.19)                | 1.12 (1.09-1.16)               |                                               |
|                        | obese 2-S        | 1.41 (1.36-1.46)                  | 1.63 (1.58-1.69)                | 1.55 (1.50-1.61)               |                                               |
|                        | obese 3-S        | 2.17 (2.06-2.29)                  | 2.96 (2.81-3.12)                | 2.72 (2.58-2.87)               |                                               |
| -related hs            | overweight-S     | 1.00                              | 1.00                            | 1.00                           | 1.00                                          |
|                        | obese 1-S        | 1.53 (1.40-1.68)                  | 1.54 (1.40-1.68)                | 1.44 (1.31-1.58)               |                                               |
|                        | obese 2-S        | 1.94 (1.75-2.15)                  | 2.33 (2.10-2.59)                | 2.06 (1.86-2.29)               |                                               |
|                        | obese 3-S        | 2.73 (2.35-3.17)                  | 3.98 (3.42-4.63)                | 3.31 (2.84-3.86)               |                                               |

Trajectory group 1 (overweight-stable) used as baseline group for comparison

\(^a\) Multivariate cox regression models adjusted for age, sex, hypertension, type 2 diabetes, atrial fibrillation and chronic kidney disease